Scancell is a clinical-stage immuno-oncology company which was founded in 1997 on research led by Professor Lindy Durrant at the University of Nottingham. The Company is operating at the forefront of immuno-oncology, an exciting field of cancer research which involves the development of immunotherapies to harness the body’s ability to generate and sustain an effective immune response against cancer.
The cancer immunotherapy market is one of the most rapidly growing markets within the biopharmaceutical industry, estimated to be worth USD100 billion by the year 2022. Immunotherapies are being evaluated in most cancer indications and their unrivalled efficacy and relatively low toxicity profile compared to chemotherapy is already leading to paradigm shifts in the treatment of many cancers. However, tumours often successfully evade the body’s own natural defence mechanism, the immune system, and not all patients are able to respond to checkpoint inhibitor-based immunotherapies. Therapeutic vaccines therefore have the potential to improve the proportion of patients who are able to benefit by initiating immune responses that convert unresponsive tumours, or so-called “cold” tumours, into “hot” ones.
The commercial potential of Scancell’s products will be defined by clinical data, either as monotherapies or in combination with checkpoint inhibitors, designed to provide increased and durable responses in patients without compromising safety and to address the unmet needs in hard to treat cancers. Scancell’s three technology platforms, ImmunoBody®, Moditope® and AvidiMab™, each offers a unique approach to cancer therapy to address all of these criteria.